Advanced Dual GIP and GLP-1 Receptor Agonist for Metabolic & Incretin Axis Optimization

Explore the cutting edge of metabolic science, obesity physiology, and endocrinology with Tirzepatide (10 MG), an elite-tier synthetic 39-amino-acid peptide engineered as a dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist. Often referred to in scientific literature as a “twinkretin,” Tirzepatide is structurally derived from the native GIP sequence and modified with two critical 2-aminoisobutyric acid (Aib) substitutions at positions 2 and 13 to provide exceptional resistance against enzymatic degradation by dipeptidyl peptidase-4 (DPP-4). Furthermore, its molecular architecture features an acylated C-20 fatty diacid moiety connected via a hydrophilic linker to the lysine residue at position 20, promoting highly reversible binding to serum albumin and extending its biological half-life to approximately 5 days.

Unlike single-hormone GLP-1 agonists, Tirzepatide binds with imbalanced affinity—mirroring native GIP potency at the GIP receptor while engaging the GLP-1 receptor with slightly lower affinity than native GLP-1. This synchronized dual signaling creates a profound metabolic compounding effect, enabling researchers to investigate enhanced glucose-dependent insulin secretion, glucagon suppression, gastric emptying kinetics, and visceral adipose tissue remodeling with unparalleled laboratory precision.

Key Product Highlights

• Dual-Incretin Agonism: Selectively activates both GIP and GLP-1 receptors simultaneously, creating a synergistic pharmacological effect that surpasses single-pathway GLP-1 receptor agonists in metabolic optimization models.

• Extended Biological Persistence: Features a C-20 fatty diacid side chain conjugated via a hydrophilic linker to Lys²⁰, driving strong albumin binding and enabling a stable, once-weekly pharmacokinetic profile (~5-day half-life).

• Enzymatic Degradation Shield: Incorporates dual amino acid modifications (Aib² and Aib¹³) that confer high stability against DPP-4 cleavage, ensuring extended cellular bioavailability in cell cultures and systemic assays.

• Pancreatic & Glycemic Control: Stimulates glucose-dependent insulin secretion from pancreatic $\beta$-cells while concurrently suppressing postprandial glucagon release from $\alpha$-cells, offering a premier model for Type 2 diabetes research.

• Appetite & Gastric Kinetics Modulation: Delays gastric emptying and regulates central nervous system satiety pathways, making it an exceptional investigative tool for caloric intake reduction and energy homeostasis.

• Pleiotropic Systemic Protection: Extensively evaluated in literature for downstream cardiometabolic benefits, including lipid profile optimization, reduction of hepatic fat accumulation, and attenuation of vascular inflammation.

• Ultra-Pure Specification: Synthesized and lyophilized at an elite ≥99% purity level (HPLC and Mass Spectrometry verified) to guarantee absolute reproducibility and zero contaminant interference in demanding laboratory assays.